Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/05/19 → 22/07/24 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
-
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?
Kobat, H., Elkonaissi, I., Foreman, E., O’Brien, M., Dorak, M. T. & Nabhani-Gebara, S., Apr 2023, In: Journal of Oncology Pharmacy Practice. 29, 3, p. 646-662Research output: Contribution to journal › Article › peer-review
-
Multiple cardiotoxicities during osimertinib therapy
Kobat, H., Davidson, M., Elkonaissi, I., Foreman, E. & Nabhani-Gebara, S., 21 Mar 2023, (E-pub ahead of print) In: Journal of Oncology Pharmacy Practice.Research output: Contribution to journal › Article › peer-review
-
Understanding cardio-oncology and potential impacts on patients
Kobat, H., Booth, C. & Nabhani-Gebara, S., 24 May 2022.Research output: Contribution to conference › Paper › peer-review